IQVIA Holdings Inc. $IQV Stock Holdings Increased by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 8.1% in the third quarter, Holdings Channel reports. The firm owned 29,694 shares of the medical research company’s stock after purchasing an additional 2,235 shares during the period. Rakuten Investment Management Inc.’s holdings in IQVIA were worth $7,987,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of IQV. BlackRock Inc. purchased a new position in shares of IQVIA in the second quarter worth $2,811,292,000. Dimensional Fund Advisors LP lifted its stake in shares of IQVIA by 4.2% during the first quarter. Dimensional Fund Advisors LP now owns 1,657,696 shares of the medical research company’s stock worth $282,657,000 after buying an additional 66,643 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of IQVIA by 9.0% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company’s stock valued at $315,772,000 after buying an additional 134,997 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of IQVIA during the second quarter valued at $240,911,000. Finally, Sumitomo Mitsui Trust Group Inc. increased its position in shares of IQVIA by 8.3% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,225,851 shares of the medical research company’s stock valued at $209,057,000 after acquiring an additional 93,779 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insiders Place Their Bets

In other IQVIA news, insider James G. Berkshire sold 2,668 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total transaction of $697,228.44. Following the sale, the insider directly owned 10,890 shares of the company’s stock, valued at approximately $2,845,883.70. This trade represents a 19.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.70% of the company’s stock.

IQVIA Stock Up 0.5%

IQV stock opened at $265.15 on Friday. The company has a market capitalization of $43.70 billion, a P/E ratio of 32.22, a price-to-earnings-growth ratio of 2.34 and a beta of 1.16. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $284.50. The firm’s fifty day simple moving average is $266.37 and its 200-day simple moving average is $210.84. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.83 and a quick ratio of 0.83.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.26 by $0.08. The firm had revenue of $4.43 billion during the quarter, compared to analysts’ expectations of $4.37 billion. IQVIA had a net margin of 8.05% and a return on equity of 30.02%. The firm’s revenue was up 8.0% compared to the same quarter last year. During the same quarter last year, the company posted $3.00 earnings per share. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 11.53 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. William Blair upgraded IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. Morgan Stanley lifted their price target on IQVIA from $240.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Thursday, September 17th. Deutsche Bank Aktiengesellschaft dropped their price target on IQVIA from $191.00 to $179.00 in a research note on Thursday, October 15th. Royal Bank Of Canada increased their price objective on IQVIA from $247.00 to $319.00 and gave the company an “outperform” rating in a report on Tuesday, September 29th. Finally, Leerink Partners raised their price objective on IQVIA from $280.00 to $310.00 and gave the stock an “outperform” rating in a research note on Thursday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $294.21.

About IQVIA

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.